Acrivon Therapeutics, Inc. (ACRV): Cash & Equivalents
$41.50M
As of 2025-12-31
$41.42M
As of 2026-06-30
+12.0%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $41.50M | +4.2% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $39.82M | +10.6% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $36.02M | +22.0% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $29.52M | -70.4% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $99.60M | n/a | 2023-03-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | 2025-12-31 | $41.50M | +4.2% |
| Citius Pharmaceuticals, Inc. (CTXR) | 2025-09-30 | $4.25M | +30.8% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $11.28M | -90.7% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $9.02M | +28.4% |
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | $45.77M | +48.6% |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $47.87M | -5.2% |
| Monopar Therapeutics (MNPR) | 2025-12-31 | $61.83M | +35.0% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $35.26M | +182.6% |
| Filana Therapeutics, Inc. (FLNA) | 2025-12-31 | $95.50M | -25.7% |
Compare ACRV, CTXR, SLN, ZOMDF side by side · Screen every company in Pharmaceutical Preparations ↗